前列腺癌的治疗。

Georgi Pirtskhalaishvili md, phd, Ronald L. Hrebinko md , Joel B. Nelson md
{"title":"前列腺癌的治疗。","authors":"Georgi Pirtskhalaishvili \n md, phd,&nbsp;Ronald L. Hrebinko \n md\n ,&nbsp;Joel B. Nelson \n md","doi":"10.1111/j.1523-5394.2001.96009.pp.x","DOIUrl":null,"url":null,"abstract":"<p><b><span>Purpose:</span></b> The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease.</p><p><b><span>Overview:</span></b> With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer.</p><p><b><span>Clinical implications:</span></b> The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.</p>","PeriodicalId":79323,"journal":{"name":"Cancer practice","volume":"9 6","pages":"295-306"},"PeriodicalIF":0.0000,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.96009.pp.x","citationCount":"25","resultStr":"{\"title\":\"The Treatment of Prostate Cancer.\",\"authors\":\"Georgi Pirtskhalaishvili \\n md, phd,&nbsp;Ronald L. Hrebinko \\n md\\n ,&nbsp;Joel B. Nelson \\n md\",\"doi\":\"10.1111/j.1523-5394.2001.96009.pp.x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b><span>Purpose:</span></b> The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease.</p><p><b><span>Overview:</span></b> With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer.</p><p><b><span>Clinical implications:</span></b> The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.</p>\",\"PeriodicalId\":79323,\"journal\":{\"name\":\"Cancer practice\",\"volume\":\"9 6\",\"pages\":\"295-306\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1111/j.1523-5394.2001.96009.pp.x\",\"citationCount\":\"25\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/j.1523-5394.2001.96009.pp.x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/j.1523-5394.2001.96009.pp.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 25

摘要

目的:本报告的目的是讨论目前可用于前列腺癌所有阶段患者的治疗方案。概述:除皮肤癌外,前列腺癌是美国男性中最常见的癌症。在当今时代,大多数患者将表现为器官局限性疾病,可治愈治疗。器官局限性疾病的治疗包括观察等待、根治性前列腺切除术、放射治疗和选择性冷冻手术。激素疗法是晚期前列腺癌患者治疗的基石。对于激素难治性前列腺癌尚无治愈方法。临床意义:针对局限性前列腺癌的几种治疗方案在制定治疗方案时需要慎重考虑。患者需要积极参与决策,他们必须了解不同类型治疗的益处和可能的并发症。晚期前列腺癌患者需要意识到,激素治疗将提供时间和缓解在大多数情况下。激素抵抗性前列腺癌对大多数常规疗法和实验疗法都是难治性的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Treatment of Prostate Cancer.

Purpose: The purpose of this report is to discuss the current treatment options available to the patient with prostate cancer in all stages of the disease.

Overview: With the exception of skin cancer, prostate cancer is the most common cancer in men in the United States. Most patients in the current era will present with organ-confined disease, amenable to curative treatment. Treatment for organ-confined disease includes watchful waiting, radical prostatectomy, radiation therapy, and cryosurgery in selective cases. Hormone therapy is the cornerstone of treatment of patients with advanced prostate cancer. There is no curative treatment for hormone-refractory prostate cancer.

Clinical implications: The availability of several therapeutic options for localized prostate cancer warrants careful consideration when planning treatment with curative intent. Patients need to be active participants in decision making, and they must be aware of the benefits and possible complications of the different types of treatment. Patients with advanced prostate cancer need to be aware that hormone treatment will provide temporization and palliation in the majority of cases. Hormone-resistant prostate cancer is refractory to most forms of conventional and experimental therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Suramin. Author Index The Collaborative Evaluation Fellows Project: Background and Overview of the Model The CEFP as a Model for Integrating Evaluation within Organizations Integrating Theory and Practice: Conceptual Frameworks of the CEFP
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1